Oppenheimer Downgrades LeMaitre Vascular (NASDAQ:LMAT) to Market Perform

LeMaitre Vascular (NASDAQ:LMAT) was downgraded by analysts at Oppenheimer from an “outperform” rating to a “market perform” rating in a note issued to investors on Friday, Marketbeat reports.

A number of other brokerages have also recently weighed in on LMAT. Barrington Research cut LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday. StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Finally, Wells Fargo & Company initiated coverage on LeMaitre Vascular in a report on Thursday, February 13th. They set an “equal weight” rating and a $95.00 price objective on the stock. Five analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $95.25.

LeMaitre Vascular Stock Down 8.1 %

NASDAQ:LMAT opened at $91.85 on Friday. The business’s 50-day moving average price is $96.89 and its two-hundred day moving average price is $94.73. LeMaitre Vascular has a twelve month low of $62.39 and a twelve month high of $109.58. The stock has a market cap of $2.07 billion, a P/E ratio of 50.19, a PEG ratio of 2.22 and a beta of 0.96.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share for the quarter, meeting the consensus estimate of $0.49. The firm had revenue of $55.81 million for the quarter, compared to analysts’ expectations of $55.99 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. On average, equities research analysts expect that LeMaitre Vascular will post 1.94 EPS for the current fiscal year.

Hedge Funds Weigh In On LeMaitre Vascular

Several institutional investors and hedge funds have recently bought and sold shares of LMAT. Creative Planning grew its position in LeMaitre Vascular by 20.7% during the 3rd quarter. Creative Planning now owns 3,594 shares of the medical instruments supplier’s stock worth $334,000 after acquiring an additional 617 shares during the last quarter. Raymond James & Associates grew its position in shares of LeMaitre Vascular by 2.6% in the 3rd quarter. Raymond James & Associates now owns 29,592 shares of the medical instruments supplier’s stock worth $2,749,000 after buying an additional 748 shares during the last quarter. Rice Hall James & Associates LLC grew its position in shares of LeMaitre Vascular by 15.7% in the 3rd quarter. Rice Hall James & Associates LLC now owns 261,306 shares of the medical instruments supplier’s stock worth $24,273,000 after buying an additional 35,383 shares during the last quarter. Oak Ridge Investments LLC bought a new stake in shares of LeMaitre Vascular in the 3rd quarter worth approximately $2,020,000. Finally, Conestoga Capital Advisors LLC grew its position in shares of LeMaitre Vascular by 1.9% in the 3rd quarter. Conestoga Capital Advisors LLC now owns 1,978,351 shares of the medical instruments supplier’s stock worth $183,769,000 after buying an additional 36,850 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.